Novel Antiplatelet Therapies for Atherothrombotic Diseases

Arterioscler Thromb Vasc Biol. 2019 Apr;39(4):546-557. doi: 10.1161/ATVBAHA.118.310955.

Abstract

Antiplatelet therapies are an essential tool to reduce the risk of developing clinically apparent atherothrombotic disease and are a mainstay in the therapy of patients who have established cardiovascular, cerebrovascular, and peripheral artery disease. Strategies to intensify antiplatelet regimens are limited by concomitant increases in clinically significant bleeding. The development of novel antiplatelet therapies targeting additional receptor and signaling pathways, with a focus on maintaining antiplatelet efficacy while preserving hemostasis, holds tremendous potential to improve outcomes among patients with atherothrombotic diseases.

Keywords: acute coronary syndrome; cardiovascular disease; hemostasis; myocardial infarction; thrombosis.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Atherosclerosis / drug therapy*
  • Humans
  • Ischemia / prevention & control
  • Platelet Aggregation Inhibitors / classification
  • Platelet Aggregation Inhibitors / pharmacology
  • Platelet Aggregation Inhibitors / therapeutic use*
  • Thrombophilia / drug therapy*

Substances

  • Platelet Aggregation Inhibitors